Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;38(4):459-474.
doi: 10.1007/s10719-021-09986-8. Epub 2021 Mar 11.

Mucins as anti-cancer targets: perspectives of the glycobiologist

Inka Brockhausen  1 , Jacob Melamed  2
Affiliations
Review

Mucins as anti-cancer targets: perspectives of the glycobiologist

Inka Brockhausen et al. Glycoconj J. 2021 Aug.

Abstract

Mucins are highly O-glycosylated glycoproteins that carry a heterogenous variety of O-glycan structures. Tumor cells tend to overexpress specific mucins, such as the cell surface mucins MUC1 and MUC4 that are engaged in signaling and cell growth, and exhibit abnormal glycosylation. In particular, the Tn and T antigens and their sialylated forms are common in cancer mucins. We review herein methods chosen to use cancer-associated glycans and mucins as targets for the design of anti-cancer immunotherapies. Mucin peptides from the glycosylated and transmembrane domains have been combined with immune-stimulating adjuvants in a wide variety of approaches to produce anti-tumor antibodies and vaccines. These mucin conjugates have been tested on cancer cells in vitro and in mice with significant successes in stimulating anti-tumor responses. The clinical trials in humans, however, have shown limited success in extending survival. It seems critical that the individual-specific epitope expression of cancer mucins is considered in future therapies to result in lasting anti-tumor responses.

Keywords: Anti-mucin antibodies; Cancer; Epitopes; Glycopeptides; Immunotherapy; MUC1; MUC4; Mucin; O-glycans; Vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brockhausen, I., Gao, Y.: In: Yurevics, E. (ed.) Structural Glycobiology: Applications in Cancer Research. Chapter 8, pp. 177–213. CRC Press, Taylor & Francis Group, Abingdon (2012)
    1. Tati, S., Fisk, J.C., Abdullah, J., et al.: Humanization of JAA-F11, a highly specific anti-Thomsen-Friedenreich Pancarcinoma antibody and InVitro efficacy analysis. Neoplasia. 19, 716–733 (2017) - PubMed - PMC
    1. Garrett, W.S.: Cancer and the microbiota. Science. 348, 80–86 (2015) - PubMed - PMC
    1. Redelman-Sidi, G., Glickman, M.S., Bochner, B.H.: The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat. Rev. Urol. 11, 153–162 (2014) - PubMed
    1. Lima, L., Severino, P.F., Silva, M., Miranda, A., Tavares, A., Pereira, S., Fernandes, E., Cruz, R., Amaro, T., Reis, C.A., Dall'Olio, F., Amado, F., Videira, P.A., Santos, L., Ferreira, J.A.: Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy. Br. J. Cancer. 109, 2106–2114 (2013) - PubMed - PMC

Publication types

LinkOut - more resources